Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism
Zhen Zhang, Jianjun Li, Yang Ou, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 62

Showing 26-50 of 62 citing articles:

Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR
Harald Schuhwerk, Thomas Brabletz
Seminars in Cancer Biology (2023) Vol. 97, pp. 86-103
Open Access | Times Cited: 10
ATR‐dependent ubiquitin‐specific protease 20 phosphorylation confers oxaliplatin and ferroptosis resistance
Jianing Tang, Guo Long, Desheng Xiao, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 10
Emerging roles of deubiquitinating enzymes in actin cytoskeleton and tumor metastasis
Ying Xue, Cong Xue, Wei Song
Cellular Oncology (2024) Vol. 47, Iss. 4, pp. 1071-1089
Closed Access | Times Cited: 3
Targeting CDK4/6 pathways and beyond in breast cancer
Domen Ribnikar, Simona Ruxandra Volovăț, Fátima Cardoso
The Breast (2018) Vol. 43, pp. 8-17
Closed Access | Times Cited: 29
Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis
Peng Wei, Jian‐Di Li, Jing‐Jing Zeng, et al.
Cancer Cell International (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 27
Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
Alessandra Dall’Acqua, Michele Bartoletti, Nastaran Masoudi-Khoram, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 3035-3035
Open Access | Times Cited: 23
Role of Metastasis Suppressor KAI1/CD82 in Different Cancers
Wei Yan, Jinny Huang, Qian Zhang, et al.
Journal of Oncology (2021) Vol. 2021, pp. 1-8
Open Access | Times Cited: 22
Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
Brian C. Velez, Christopher Petrella, Kathleen H. DiSalvo, et al.
Oncology Reports (2022) Vol. 49, Iss. 2
Open Access | Times Cited: 14
Down‐regulation of RCC1 sensitizes immunotherapy by up‐regulating PD‐L1 via p27kip1/CDK4 axis in non‐small cell lung cancer
Xiaozhu Zeng, Maoxi Zhong, Yumeng Yang, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 25, Iss. 8, pp. 4136-4147
Open Access | Times Cited: 18
The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells
Małgorzata Kucińska, Julia Pospieszna, Jing Tang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116892-116892
Open Access | Times Cited: 2
CDK4/6-USP51 axis regulates lung adenocarcinoma metastasis through ZEB1
Jianjun Li, Xuechun Xiao, Hang Wang, et al.
Cancer Gene Therapy (2022) Vol. 29, Iss. 8-9, pp. 1181-1192
Closed Access | Times Cited: 12
The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response
Harald Schuhwerk, Julia Kleemann, Pooja Gupta, et al.
Cell Reports (2022) Vol. 41, Iss. 11, pp. 111819-111819
Open Access | Times Cited: 12
Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment
Meiling Huang, Guang-Tai Shen, Nanlin Li
World Journal of Clinical Cases (2022) Vol. 10, Iss. 32, pp. 11690-11701
Open Access | Times Cited: 10
Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies
Chun‐Ming Chang, Ho Yin Pekkle Lam
Anticancer Research (2023) Vol. 43, Iss. 12, pp. 5283-5298
Open Access | Times Cited: 6
Fisetin suppresses cigarette smoke extract-induced epithelial to mesenchymal transition of airway epithelial cells through regulating COX-2/MMPs/β-catenin pathway
Hina Agraval, Jiten R. Sharma, Nutan Prakash Vishwakarma, et al.
Chemico-Biological Interactions (2021) Vol. 351, pp. 109771-109771
Closed Access | Times Cited: 14
In vivo CRISPR screens identify RhoV as a pro‐metastasis factor of triple‐negative breast cancer
Ming‐Liang Jin, Yue Gong, Peng Ji, et al.
Cancer Science (2023) Vol. 114, Iss. 6, pp. 2375-2385
Open Access | Times Cited: 5
The emerging potentials of lncRNA DRAIC in human cancers
Qinfan Yao, Xiuyuan Zhang, Dajin Chen
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
POLD2 is activated by E2F1 to promote triple-negative breast cancer proliferation
Zhen Zhang
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery
Sixuan Li, Hongquan Zhang, Xiaofan Wei
Life (2021) Vol. 11, Iss. 9, pp. 965-965
Open Access | Times Cited: 11
SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
Jianjun Li, Chun-Chun Qi, Shanshan Shao, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 4
Abemaciclib and Vacuolin-1 decrease aggregate-prone TDP-43 accumulation by accelerating autophagic flux
Yoshinori Tanaka, Lina Kozuma, Hirotsugu Hino, et al.
Biochemistry and Biophysics Reports (2024) Vol. 38, pp. 101705-101705
Open Access | Times Cited: 1
Study on inhibition of Britannin on triple-negative breast carcinoma through degrading ZEB1 proteins
Hong Lu, Zhengyu Wu, Yijun Wang, et al.
Phytomedicine (2022) Vol. 104, pp. 154291-154291
Closed Access | Times Cited: 7
Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors
Wei Guan, Songlin Li, Zhimin Zhang, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 20, pp. 2844-2853
Open Access | Times Cited: 6
USP31 serves as a potential biomarker for predicting prognosis and immune responses for clear cell renal cell carcinoma via single‐cell and bulk RNA‐sequencing
Yaoyu Yu, Guihua Chen, Chao Jiang, et al.
The Journal of Gene Medicine (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 3
CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER + breast cancer
Chih-Yi Lin, Chung-Jen Yu, Chun‐Yu Liu, et al.
Clinical & Translational Oncology (2022) Vol. 24, Iss. 11, pp. 2120-2135
Closed Access | Times Cited: 5

Scroll to top